Codiak Biosciences is developing exosome-based therapies to treat a wide range of diseases. Exosomes are small lipid particles secreted by cells that aid in intercellular communication. Codiak is leveraging this natural cellular transfer mechanism to develop their proprietary engEx platform that is expanding the innate properties of exosomes to identify novel exosome therapeutics candidates. This engineering involves identifying exosome-associated proteins so that Codiak can redirect tropism to ensure exosomes reach the specific target cell and loading exosomes with different types of therapeutic molecules from nucleic acids to small molecules. Currently, Codiak is applying their technology to oncology, neurology, neuromuscular disease and infectious diseases.

<p>Codiak Biosciences is developing exosome-based therapies to treat a wide range of diseases. Exosomes are small lipid particles secreted by cells that aid in intercellular communication. Codiak is leveraging this natural cellular transfer mechanism to develop their proprietary engEx platform that is expanding the innate properties of exosomes to identify novel exosome therapeutics candidates. This engineering involves identifying exosome-associated proteins so that Codiak can redirect tropism to ensure exosomes reach the specific target cell and loading exosomes with different types of therapeutic molecules from nucleic acids to small molecules. Currently, Codiak is applying their technology to oncology, neurology, neuromuscular disease and infectious diseases.</p>


Codiak Biosciences

Founded: 2015
Location: Cambridge, MA
Employee range: 101-250
Funding: 100-500M

Short description:

Drug notes:

Long description:

Jobs: